C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel therapeutic candidates using targeted protein degradation. Headquartered in Watertown, Massachusetts, the company utilizes its proprietary TORPEDO platform to design small-molecule medicines, including MonoDAC and BiDAC degraders. These therapies aim to overcome drug resistance and target previously undruggable proteins by directing the body's natural protein recycling system to degrade disease-causing proteins. The company's clinical pipeline is primarily focused on oncology, with lead candidates such as cemsidomide for multiple myeloma and other hematologic malignancies, as well as programs targeting solid tumors. Additionally, C4 Therapeutics collaborates with major pharmaceutical companies, including Roche and Biogen, to expand the application of its degrader technologies across multiple therapeutic areas.
